James Christopher Passin

James Christopher Passin appears in our data through filings on BioVaxys Technology Corp. shares, published by SEDI. Over a trading history stretching from 6 September 2024 to 18 November 2025, the count stands at 8 filings.

In open-market terms, that means 1 purchase worth €1,901 on one side and 2 sales worth €538k on the other. Sales outweigh purchases by €536k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2025, the count stands at 1 purchase and 1 sale.

Most recently, on 20 November 2025, the filings show a transaction worth €155k in BioVaxys Technology Corp. The latest purchase dates back some time: it was published 544 days ago, on 28 April 2025. Typically, a trade is published a median of 4 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEDI disclosures alone and does not predict where the share price will go.